MC1R variants increase melanoma risk in families with CDKN2A mutations: A meta-analysis

被引:65
|
作者
Fargnoli, Maria Concetta [2 ]
Gandini, Sara [1 ]
Peris, Ketty [2 ]
Maisonneuve, Patrick [1 ]
Raimondi, Sara [1 ]
机构
[1] European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy
[2] Univ Aquila, Dept Dermatol, I-67100 Laquila, Italy
关键词
Melanocortin-1-receptor; Cyclin-dependent kinase inhibitor; 2A; Familial melanoma; Genetic epidemiology; MULTIPLE PRIMARY MELANOMA; CUTANEOUS MELANOMA; PRONE FAMILIES; SUSCEPTIBILITY GENES; CDK4; MUTATIONS; HAIR COLOR; POPULATION; PENETRANCE; PHENOTYPE; CARRIERS;
D O I
10.1016/j.ejca.2010.01.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim of the study: We performed a meta-analysis to assess whether MC1R variants increase the risk of melanoma in CDKN2A mutation carriers of melanoma-prone families. Methods: Data from 96 CDKN2A-positive melanoma-prone families from seven independent populations of Europe, United States and Australia were included in the analysis. Summary risk estimates were calculated by random-effect models. We explored between-study heterogeneity and publication bias. Association between MC1R variants and age at diagnosis was assessed by the non-parametric Wilcoxon test. Results: CDKN2A mutation carriers with 1 MC1R variant showed a double melanoma risk as compared to CDKN2A mutation carriers without MC1R variants (Summary OR; 95%CI: 2.2; 1.1-4.5). MC1R heterozygous subjects had no significantly higher melanoma risk than wild-type subjects (1.6; 0.5-5.4) while carriers of multiple MC1R variants had a more than four-times higher melanoma risk (4.6; 1.3-16.4). Carriers of red hair colour (RHC) variants showed an increased melanoma risk with a Summary OR of 3.5 (95%CI: 1.3-9.9). CDKN2A mutation carriers with MC1R variants had a statistically significant lower median age at melanoma diagnosis than CDKN2A mutation carriers with no MC1R variants (37 years versus 47 years, p-value <0.0001). Conclusion: MC1R variants significantly increase penetrance of CDKN2A mutations in melanoma-prone families, especially with respect to multiple MC1R variants and to RHC variants. A significant anticipation of melanoma diagnosis is observed in CDKN2A mutation carriers with MC1R variants. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1413 / 1420
页数:8
相关论文
共 50 条
  • [41] Screening for tumour suppressor p16(CDKN2A) germline mutations in Israeli melanoma families
    Yakobson, EA
    Zlotogorski, A
    Shafir, R
    Cohen, M
    Icekson, M
    Landau, M
    Brenner, S
    Usher, S
    Peretz, H
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 1998, 36 (08) : 645 - 648
  • [42] A Large French Case-Control Study Emphasizes the Role of Rare Mc1R Variants in Melanoma Risk
    Hu, Hui-Han
    Benfodda, Meriem
    Dumaz, Nicolas
    Gazal, Steven
    Descamps, Vincent
    Bourillon, Agnes
    Basset-Seguin, Nicole
    Riffault, Angelique
    Ezzedine, Khaled
    Bagot, Martine
    Bensussan, Armand
    Saiag, Philippe
    Grandchamp, Bernard
    Soufir, Nadem
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [43] Analysis of MC1R variants in Indian oculocutaneous albinism patients: highlighting the risk of skin cancer among albinos
    Sengupta, Mainak
    Sarkar, Devroop
    Mondal, Maitreyee
    Samanta, Swapan
    Sil, Asim
    Ray, Kunal
    JOURNAL OF GENETICS, 2013, 92 (02) : 305 - 308
  • [44] The MC1R Melanoma Risk Variant p.R160W Is Associated with Parkinson Disease
    Tell-Marti, Gemma
    Anton Puig-Butille, Joan
    Potrony, Miriam
    Badenas, Celia
    Mila, Montserrat
    Malvehy, Josep
    Jose Marti, Maria
    Ezquerra, Mario
    Fernandez-Santiago, Ruben
    Puig, Susana
    ANNALS OF NEUROLOGY, 2015, 77 (05) : 889 - 894
  • [45] Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population
    Lamperska, K
    Karczewska, A
    Kwiatkowska, E
    Mackiewicz, A
    ACTA BIOCHIMICA POLONICA, 2002, 49 (02) : 369 - 376
  • [46] CM-Score: a validated scoring system to predict CDKN2A germline mutations in melanoma families from Northern Europe
    Potjer, Thomas P.
    Helgadottir, Hildur
    Leenheer, Mirjam
    van der Stoep, Nienke
    Gruis, Nelleke A.
    Hoiom, Veronica
    Olsson, Hakan
    van Doorn, Remco
    Vasen, Hans F. A.
    van Asperen, Christi J.
    Dekkers, Olaf M.
    Hes, Frederik J.
    JOURNAL OF MEDICAL GENETICS, 2018, 55 (10) : 661 - 668
  • [47] The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis
    Xing, X.
    Cai, W.
    Shi, H.
    Wang, Y.
    Li, M.
    Jiao, J.
    Chen, M.
    BRITISH JOURNAL OF CANCER, 2013, 108 (12) : 2542 - 2548
  • [48] MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: A pooled-analysis from the M-SKIP project
    Pasquali, Elena
    Garcia-Borron, Jose C.
    Fargnoli, Maria Concetta
    Gandini, Sara
    Maisonneuve, Patrick
    Bagnardi, Vincenzo
    Specchia, Claudia
    Liu, Fan
    Kayser, Manfred
    Nijsten, Tamar
    Nagore, Eduardo
    Kumar, Rajiv
    Hansson, Johan
    Kanetsky, Peter A.
    Ghiorzo, Paola
    Debniak, Tadeusz
    Branicki, Wojciech
    Gruis, Nelleke A.
    Han, Jiali
    Dwyer, Terry
    Blizzard, Leigh
    Landi, Maria Teresa
    Palmieri, Giuseppe
    Ribas, Gloria
    Stratigos, Alexander
    Council, M. Laurin
    Autier, Philippe
    Little, Julian
    Newton-Bishop, Julia
    Sera, Francesco
    Raimondi, Sara
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (03) : 618 - 631
  • [49] MC1R major variants are a risk factor of sleep lines in Caucasian women
    Jdid, R.
    Ezzedine, K.
    Latreille, J.
    Galan, P.
    Hercberg, S.
    Malvy, D.
    Tschachler, E.
    Guinot, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (06) : 805 - 809
  • [50] CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies
    Helgadottir, Hildur
    Hoiom, Veronica
    Tuominen, Rainer
    Jonsson, Goran
    Mansson-Brahme, Eva
    Olsson, Hakan
    Hansson, Johan
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (09) : 2220 - 2226